Modulation by desensitized nicotinic receptors on metabolism of DA in striatum derived from the hemiparkinsonian model

doi:10.13459/j.cnki.cjap.2016.06.002

Abstract

Abstract: Objective: The purpose of this study was to investigate the effects of desensitized nicotinic receptors (nAChRs) on striatal dopaminergic system in the hemiparkinsonian rats treated with 6-hydroxydopamine (6-OHDA). Methods: We examined the effects of desensitized nAChRs on the levels of dopamine (DA) and its metabolites, mRNA expression of dopamine receptor D1,D2 and monoamine oxidase B (MAO-B) in the striatum of 6-OHDA-lesioned rats using high-performance liquid chromatography and reverse transcription-polymerase chain reaction. Results: The results showed that nAChRs desensitization following repeated nicotine stimulation could reverse significantly the decrease of striatal DA and its metabolites levels and the increase in DA turnover in lesioned side striatum of hemiparkinsonian rats. Dopamine D1 receptor mRNA expression increased significantly, whereas dopamine D2 receptor mRNA expression remained unchanged in lesioned side striatum of nicotine-treated rats compared to 6-OHDA-lesioned rats when nAChRs were desensitized. Meanwhile, nicotine-treated rats displayed a significant decrease in MAO-B mRNA expression in lesioned side striatum compared to 6-OHDA-lesioned rats after nAChRs desensitization. Conclusion: These results suggest that nAChRs desensitization could promote DA level, upregulate dopamine D1 receptor expression and downregulate MAO-B expression in striatum of hemiparkinsonian rats.

Key words: Parkinson's disease, nicotine, nicotine acetylcholine receptor, desensitization

Fu-rong HAN, Hai WANG. Modulation by desensitized nicotinic receptors on metabolism of DA in striatum derived from the hemiparkinsonian model[J]. CJAP, 2016, 32(6): 487-493.

References

1. Sauer H, Oertel WH. Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine:a combined retrograde tracing and immunocytochemical study in the rat[J]. Neuroscience, 1994, 59(2):401-415.
2. Dauer W, Przedborski S. Parkinson's disease:mechanisms and models[J]. Neuron, 2003, 39(6):889-909.
3. Morens DM, Grandinetti A, Reed D, et al. Smoking-associated protection from Alzheimer's and Parkinson's disease[J]. Lancet, 1994, 343(8893):356-357.
4. Gorell JM, Rybicki BA, Johnson CC, et al. Smoking and Parkinson's disease:a dose-response response relationship[J]. Neurology, 1999, 52(1):115-119.
5. Damsma G, Day J, Fibiger HC. Lack of tolerance to nicotine-induced dopamine release in the nucleus accumbens[J]. Eur J Pharmacol, 1989, 168(3):363-368.
6. Parain K, Marchand V, Dumery B, et al. Nicotine, but not cotinine partially protects dopaminergic neurons against MPTP-induced degeneration in mice[J]. Brain Res, 2001, 890(2):347-350.
7. Karlin A. Emerging structure of the nicotinic acetylcholine receptors[J]. Nat Rev Neurosci, 2002, 3(2):102-114.
8. Voitenko SV, Bobryshev AY, Skok VI. Intracellular regulation of neuronal nicotinic cholinoreceptors[J]. Neurosci Behav Physiol, 2000, 30(1):19-25.
9. Nisell M, Nomikos GG, Hertel P, et al. Conditionindependent sensitization of locomotor stimulation and mesocortical dopamine release following chronic nicotine treatment in the rat[J]. Synapse, 1996, 22(4):369-381.
10. Wang H, Sun XL. Desensitized nicotinic receptors in brain[J]. Brain Res Rev, 2005, 48(3):420-437.
11. Liu Y, Wang Y, Sun XL, et al. Modulation of nicotine on functions and geneexpression of monoamine receptor in the brain[J]. Chin J Behav Med Sci, 2003, 12(6):619-621.
12. Sun XL, Liu Y, Hu G, et al. Activities of cAMP-dependent protein kinase and protein kinase C are modulated by desensitized nicotinic receptors in the rat brain[J]. Neurosci Lett, 2004, 367(1):19-22.
13. Cai G, Wang HY, Friedman E. Increased dopamine receptor signaling and dopamine receptor-G protein coupling in denervated striatum[J]. J Pharmacol Exp Ther, 2002, 302(3):1105-1112.
14. Araki T, Tanji H, Kato H, et al. Alterations of second messenger systems in the rat brain after 6-hydroxydopamine lesions of the medial forebrain bundle[J]. Eur J Pharmacol Sci, 1999, 8(4):261-267.
15. Han FR, Wang H. Effects of desensitized nicotinic receptors on rotational behavior in 6-hydroxydopamine model of Parkinson's disease[J]. Neurosci Lett, 2007, 415(3):200-204.
16. Paxinos G, Watson C. The rat brain in stereotaxic coordinates[M]. Academic Press, San Diego, CA, 1986.
17. Hudson JL, van Horne CG, Stromberg I, et al. Correlation of apomorphine-and amphetamine-induced turning with nigrostriatal dopamine content in unilateral 6-hydroxydopamine Lesioned rats[J]. Brain Res, 1993, 626(1-2):167-174.
18. Rowell PP, Li M. Dose-response relationship for nicotine-induced up-regulation of rat brain nicotinic receptors[J]. J Neurochem, 1997, 68(5):1982-1989.
19. Flores G, Liang JJ, Sierra A, et al. Expression of dopamine receptors in the subthalamic nucleus of the rat:characterization using reverse transcriptase-polymerase chain reaction and autoradiography[J]. Neuroscience, 1999, 91(2):549-556.
20. Hurley MJ, Mash DC, Jenner P. Markers for dopaminergic neurotransmission in the cerebellum in normal individuals and patients with Parkinson's disease examined by RTPCR[J]. Eur J Neurosci, 2003, 18(9):2668-2672.
21. Joghataie MT, Roghani M, Negahdar F, et al. Protective effect of caffeine against neurodegeneration in a model of Parkinson's disease in rat:behavioral and histochemical evidence[J]. Parkinsonism Relat Disord, 2004, 10(8):465-468.
22. Ryoo HL, Pierrotti D, Joyce JN. Dopamine D3 receptor is decreased and D2 receptor is elevated in the striatum of Parkinson's disease[J]. Mov Disord, 1998, 13(5):788-797.
23. Robinet PM, Bardo MT. Dopamine D3 receptors are involved in amphetamine-induced contralateral rotation in 6-OHDA lesioned rats[J]. Pharmacol Biochem Behav, 2001, 70(1):43-54.
24. Shachar DB, Kahana N, Kampel V, et al. Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lesion in rats[J]. Neuropharmacology, 2004, 46(2):254-263.
25. Xu Z, Cawthon D, McCastlain KA, et al. Selective alterations of gene expression in mice induced by MPTP[J]. Synapse, 2005, 55(1):45-51.
26. Yuan H, Sarre S, Ebinger G, et al. Histological, behavioural and neurochemical evaluation of medial forebrain bundle and striatal 6-OHDA lesions as rat models of Parkinson's disease[J]. J Neurosci Methods, 2005, 144(1):35-45.
27. Benwell ME, Balfour DJ. Regional variation in the effects of nicotine on catecholamine overflow in rat brain[J]. Eur J Pharmacol, 1997, 325(1):13-20.
28. Wonnacott S. Presynaptic nicotinic ACh receptors[J]. Trends Neurosci, 1997, 20(2):92-98.
29. Olanow CW. The scientific basis for the current treatment of Parkinson's disease[J]. Annu Rev Med, 2004, 55:41-60.
30. Samii A, Nutt JG, Ransom BR. Parkinson's disease[J]. Lancet, 2004, 363(9423):1783-1793.
31. Chase TN, Engber TM, Mouradian MM. Contribution of dopaminergic and glutamatergic mechanisms to the pathogenesis of motor response complications in Parkinson's disease[J]. Adv Neurol, 1996, 69:497-501.
32. Goetz CG, Delong MR Richard MD. Neurosurgical horizons in PD[J]. Neurology, 1993, 43(1):1-12.